Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms.
Core Innovation
The disclosed subject matter provides substituted tetracycline compounds represented by Formula I through Formula XVI, encompassing minocycline and sancycline derivatives, or pharmaceutically acceptable salts thereof. Synthetic transformations yield diverse 7-, 9-, and 10-substituted derivatives bearing substituents such as aminoalkyl, heteroaryl, oxime, and alkoxycarbonyl groups. Pharmaceutical compositions comprising the substituted compounds and a pharmaceutically acceptable carrier are also provided, although the specific technical problem being solved is not explicitly described in patent.
The disclosure details compound characterizations alongside antibacterial, cytotoxicity, phototoxicity, oxidation-stability, and in vivo biological evaluations. Several substituted tetracycline derivatives demonstrate antibacterial efficacy and provide 100% survival in infection models, while compound B displays an enhanced oxidation half-life over minocycline. In addition, compounds A and P reduce carrageenan-induced paw edema with efficacy comparable to or exceeding standard tetracyclines in tetracycline-responsive states.
Claims Coverage
The provided claims identify two independent claims directed to substituted tetracycline compounds, comprising two inventive features.
Substituted tetracycline compound of formula I
A compound of formula I in which X is CR6′R6 or C=CR6′R6; E is NR7dR7e or OR7f; R2, R2′, R4′, R4a, and R4b are independently hydrogen or alkyl; R3, R10, R11, and R12 are hydrogen; R4 is NR4aR4b; R5 and R5′ are independently hydroxyl, hydrogen, or alkyl; R6 and R6′ are independently hydrogen, hydroxyl, or alkyl; R7a, R7b, R7c, R7d, R7e, and R7f are independently hydrogen, alkyl, alkenyl, aryl, or arylalkyl, or specified groups are linked to form a ring; R8 is hydrogen; and R9 is hydrogen, alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, or aminoalkyl; or a pharmaceutically acceptable salt thereof.
Compound of depicted structure
A compound of the structure depicted in the claim, or a pharmaceutically acceptable salt thereof.
The independent claims cover substituted tetracycline compounds defined by formula I and a separately depicted chemical structure, or pharmaceutically acceptable salts thereof.
Stated Advantages
Many of the compounds showed antibacterial activity across the tested organisms.
Compound B had a reported oxidation half-life of 495 seconds, compared with 8.2 seconds for minocycline.
Several compounds provided 100% survival in a mouse S. aureus infection model at tested doses.
Compounds A and P reduced carrageenan-induced rat paw edema, with activity comparable to or better than doxycycline or minocycline.
Documented Applications
Treatment of a bacterial, viral, or parasitic infection in a subject by administering an effective amount of the claimed compound.
A pharmaceutical composition for treating malaria.
Treatment of tetracycline-responsive states, including bacterial infections, inflammation, and neoplasms.
Interested in licensing this patent?